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Abstract
Mesenteric ischemia/reperfusion is a clinical emergency with high morbidity and mortality
due to the transient reduction of blood supply to the bowel. In recent years, the critical contri-
bution of gut microbiome to human health and proper gastrointestinal functions has gradu-
ally emerged. In the current study, we investigated the protective effects of five days
supplementation with Bifidobacterium bifidum PRL2010 in a murine model of gut ischemia/
reperfusion. Our findings indicate that animals pretreated with B. bifidum PRL2010 showed
lower neutrophil recruitment in the lungs, remarkably reduced bacterial translocation and
decreased transcription levels of TNFalpha and IL-10 both in liver and kidneys, at the same
time increasing those of IL-12 in kidneys. Inhibiting the adhesion of pathogenic bacteria and
boosting host innate immunity responses are among the possible protective mechanisms
enacted by the probiotic. These results demonstrate that short-period treatment with B. bifi-
dum PRL2010 is a potential strategy to dampen remote organ injury due to mesenteric
ischemia/reperfusion.
1. Introduction
Mesenteric ischemia/reperfusion (I/R) is a life-threatening clinical emergency associated with
different pathological conditions and surgical procedures, such as organ transplantation,
bowel strangulation, vascular surgery and shock [1]. Gut epithelial cells are highly sensitive to
I/R: the poor oxygenation, which results from the transient interruption of blood supply to the
bowel, followed by reperfusion triggers an intense inflammatory response that typically causes
progressive distal organ impairment and, consequently, a high rate of morbidity and mortality
[2]. Several studies have shown that the most important consequences of mesenteric I/R injury
are the loss of intestinal mucosal barrier function and subsequent translocation of bacteria and
endotoxins from the gut into the blood and to distant organs [3, 4].
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The human gut microbiota is a highly complex biological ecosystem that plays important
roles in host health, such as immune stimulation, gut-mediated metabolism of essential nutri-
ents, exclusion of gut pathogens and maintenance of appropriate mucosal function and intesti-
nal barrier [5, 6]. In fact, a negative disturbance of gut microbiota composition, also known as
dysbiosis, may impact on human health and may cause several gastrointestinal diseases [7–9].
Accordingly, probiotics, live non-pathogenic microorganism supplements, thanks to their
documented ability to modulate the enteric microflora and to confer beneficial effects to the
host through the modulation of immune and inflammatory responses [10, 11], have been pro-
posed for the management of several intestinal disorders.
Bifidobacteria are dominant bacterial components of the gut microbiota in mammals,
including humans during infancy. They therefore represent a valuable microbial prototype to
investigate gut microbiota development, including factors that influence microbial establish-
ment and persistence in the gut [12]. Furthermore, bifidobacteria have been evaluated in the
prevention and treatment of different gastrointestinal infections such as Clostridium difficile
infection as well as of intestinal disorders such as ulcerative colitis and Crohn’s disease [13].
In this context, we decided to focus our attention on Bifidobacterium bifidum PRL2010 (B.
bifidum PRL2010), isolated from three-months old infants, that represents a strain very well
described phenotypically and genotypically [14–16]. In previous in vitro and animal studies we
have shown that B. bifidum PRL2010 is able to (i) adhere to the intestinal mucosa, (ii) prevent
enteric pathogen colonization, and (iii) maintain gut homeostasis by down-regulating expres-
sion of chemokines and heat shock proteins and up-regulating defensins and tight junction
proteins in the murine host [14–16].
Starting from these premises, the aim of the current study was to evaluate the effects of oral
pre-treatment with B. bifidum PRL2010 on the local and systemic inflammatory responses trig-
gered by mesenteric I/R in mice.
2. Materials and methods
2.1 Animals
Female adult Swiss mice, weighing approximately 18–25 g (Charles River, Italy), were kept
under standard laboratory conditions with a controlled 12 hours light/dark cycle in a tempera-
ture-controlled room (22˚C) with free access to water and standard chow. Mice were fasted 12
h before the experiment with free access to water. This investigation conformed to rules for the
care and use of laboratory animals of the European Community and was in accordance with
Italian Law (DLGS 26/2014). All procedures were approved by the University of Parma, and
by the Italian Ministry of Health as executed by 99–2014 the Institutional Animal Care and
Use Committee (Dipartimento per la Sanità Pubblica Veterinaria, la Nutrizione e la Sicurezza
degli Alimenti Direzione Generale della Sanità Animale e del Farmaco Veterinario) and all
efforts were made to minimize suffering.
2.2 Experimental protocol and ischemia/reperfusion (I/R) surgical
procedure
Mice were administered for five days with B. bifidum PRL2010 109 cells per day, prepared as
previously described [17]. They were randomly divided into the following two groups: i) mice
subjected to mesenteric I/R and ii) sham operated (SO) mice. Corresponding control animals
were represented by I/R or SO mice supplemented with vehicle (glucose 5%).
After 12h fasting with free access to water, mice were anaesthetized with pentobarbital (70
mg/kg i.p.) and, after a midline laparotomy, the small bowel was displaced to the left side. The
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superior mesenteric artery (SMA) was identified and temporarily occluded with a microvascu-
lar clip. After 45 minutes of ischemia, during which the intestine was kept moisturized through
a wet cotton gauze, the clamp was removed and reperfusion was allowed. The midline incision
of the abdominal wall was then closed by two-layer sutures. Sham operated (SO) mice were
subjected to the same surgical procedure and intestinal manipulation without occlusion of the
SMA. After five hours of reperfusion, animals were euthanized through CO2 inhalation and
distal small intestine (jejunum and ileum), lung, liver, kidneys, spleen and blood were collected
and processed for histological, biochemical or quantitative-real time PCR analysis.
2.3 Bacterial strains and culture conditions
B. bifidum PRL2010 cultures were incubated in anaerobic atmosphere (2.99% H2, 17.01% CO2
and 80% N2) in a chamber (Concept 400, Ruskin) in the Man-Rogosa-Sharp (MRS) (Scharlau
Chemie, Barcelona, Spain) supplemented with 0.05% (w/v) L-cysteine hydrochloride and incu-
bated at 37˚C for 16 h.
2.4 Murine exposure to bifidobacteria
Each animal was trained to spontaneously drink 100 μl of vehicle (5% glucose) over less than 5
minutes from a syringe daily for one week. After training, mice were administered, in the
same voluntary way, 100 μl of suspension containing approximately 109 CFU cells of B. bifi-
dum PRL2010 for five consecutive days. Bacterial inocula were prepared by growing bifidobac-
terial cells, anaerobically overnight at 37˚C in MRS broth. Cultures were harvested by
centrifugation (3000 rpm for 8 minutes), washed and resuspended in 100 μl of vehicle (5% glu-
cose). The viable count of each inoculum was determined by retrospective plating on MRS.
Control animals received during the same period only 100 μl liquid vehicle (i.e., 5% glucose
solution without bacterial cells).
2.5 Detection of bifidobacteria by quantitative PCR (qPCR) in fecal samples
Evaluation of the presence of bifidobacteria in the murine fecal samples, collected before and
after 1, 4 and 7 days from the beginning of supplementation, was performed by quantitative
real-time qPCR using previously described genus-specific primers [18, 19]. In order to esti-
mate the level of bifidobacterial transiently present in each animal, a qPCR approach using
strain specific primers based on strain-specific genes were used on DNA extracted from fecal
samples. Murine fecal samples were subjected to DNA extraction using the QIAampDNA
Stool Mini kit following the manufacturer’s instructions (Qiagen Ltd., Strasse, Germany).
For B. bifidum PRL2010, primers Bbif_0282Fw (5’-GCGAACAATGATGGCACCTA-3’)
and Bbif_0282Rv (5’-GTCGAACACCACGACGATGT-3’) were used, which target a unique
specific sequence identified in the genome of strain PRL2010 [20].
qPCR reactions were performed on MicroAmp optical plates sealed with MicroAmp optical
caps (Applied Biosystems, Foster City, CA) and amplifications were carried out in CFX96
(Biorad) using SYBR Green PCR Master Mix (Applied Biosystems). Thermal cycling consisted
of an initial cycle of 95˚C for 10 min followed by 40 cycles of 95˚C for 15 sec and 60˚C for 1
min. DNA extracts from cultures of B. bifidum PRL2010 were used to obtain a standard curve.
Samples were analyzed in duplicate in at least two independent PCR runs.
2.6 Bacterial translocation to distant organs
In order to evaluate bacterial translocation, animals were euthanized and blood, kidney, liver
and spleen were removed and then used for DNA extraction. To estimate the overall levels of
Intestinal ischemia/reperfusion injury and Bifidobacterium bifidum PRL2010
PLOS ONE | https://doi.org/10.1371/journal.pone.0202670 August 30, 2018 3 / 16
bacteria a qRT-PCR approach was used involving the eubacterial universal primers Pro-
bio_Rev (5’-ATTACCGCGGCTGCT-3’)and Probio_Uni (5’-CCTACGGGRSGCAGCAG-
3’) employing qRT-PCR conditions as previously described [21].
2.7 Myeloperoxidase activity
Myeloperoxidase (MPO) activity, index of tissue neutrophil infiltration, was determined in
intestinal and pulmonary tissues according to Krawisz’s modified method [22]. Briefly, intesti-
nal tissue was homogenized (1:10, v v−1) in a solution containing aprotinin 1 μg ml−1 in 100
mM potassium phosphate buffer (pH 7.4) and centrifuged for 20 min at 7000 x g at 4˚C. Pellets
were re-homogenized (1:5, v v−1) in 50 mM potassium phosphate buffer (pH 6.0) containing
0.5% hexadecylthrimethyl-ammonium bromide and aprotinin 1 μg ml−1, subjected to three
cycles of freezing (20 min -196˚C) and thawing (20 min 37˚C) and centrifuged for 30 min at
5000 x g at 4˚C. 100 μl of the supernatant was mixed with 900 μl of a buffer solution containing
o-dianisidine (0.167 mg ml−1) and 0.0005% H2O2. The rate of change in absorbance was mea-
sured spectrophotometrically at 470 nm. One unit of MPO was defined as the quantity of
enzyme degrading 1 μmol of peroxide per minute at 25˚C. Data were expressed in units/gram
of dry weight tissue.
2.8 Malondialdehyde assay
The formation of malondialdehyde (MDA) was used as index of lipoperoxidation. Tissue
MDA levels were determined following Ohkawa’s method [23]. Ileal samples were homoge-
nized in 1.15% KCl solution (1:10, v v−1). 100 μl of the homogenate was added to a solution
containing 200 μl of 8.1% sodium dodecyl sulphate, 1.5 ml of 20% acetic acid (pH 3.5), 1.5
ml of 0.8% thiobarbituric acid and 700 μl distilled water. Samples were then boiled for 1 h at
95˚C and centrifuged at 3000×g for 10 min. The absorbance of the supernatant was mea-
sured by spectrophotometry at 532 nm. Data were expressed in nmol/gram of dry weight
tissue.
2.9 Vascular permeability
To assess interstitial edema formation, index of increased capillary permeability of intestinal
mucosa, intestinal samples were removed and opened along the anti-mesenteric border and
wet weight was recorded. After 24 h at room temperature the samples were then weighed to
obtain the dry weight. Tissue water content was calculated using the wet-to-dry weight ratio
according to Moore-Olufemi: (wet weight − dry weight)/dry weight [24].
2.10 RNA isolation, reverse transcription and gene expression
Total RNA was isolated following a previously described protocol from liver and kidneys [21].
Reverse transcription to cDNA was performed with iScript Select cDNA synthesis kit (Bio-
Rad Laboratories) using the following thermal cycle: 5 min at 25˚C, 30 min at 45˚C and 8 min
at 85˚C. The mRNA expression levels of cytokines were analyzed with SYBR green technology
in quantitative Real-Time PCR (Biorad) on a Bio-RAD CFX96 system. Gene expression was
normalized relative to a housekeeping gene as previously described [25].
2.11 Intestinal and lung histology
Samples of intestine and lungs were collected from the different groups of animals to deter-
mine the level of histological injury. After euthanasia, the trachea was cannulated with PE-50
tubing and the lungs were fixed in situ via the cannula with 10% neutral buffered formalin,
Intestinal ischemia/reperfusion injury and Bifidobacterium bifidum PRL2010
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before the thorax was opened. Intestinal tissues were excised, flushed with saline and immer-
sion-fixed in 10% neutral buffered formalin overnight. Fixed tissues were then dehydrated and
embedded in paraffin. Transverse 5-μm sections were cut, stained with hematoxylin-eosin and
examined in a light microscope (Nikon Eclipse E800) by a person unaware of the treatment.
For each animal, at least five sections were cut from the distal portion of small intestine (jeju-
num-ileum) and from lungs. Intestinal mucosal damage was graded according to Chiu’s score
[26] (0, normal mucosa; 1, development of sub-epithelial Gruenhagen’s space; 2, lifting of epi-
thelial layer from the lamina propria; 3, massive epithelial lifting; 4, denuded villi; 5, digestion
and disintegration of lamina propria). The degree of lung injury was determined by applying
the scoring system described by Matute-Bello et al. [27] that graded congestion of alveolar sep-
tae (0: septae thin and delicate; 1: congested alveolar septae in 1/3-2/3 of the field; 3: congested
alveolar septae in>2/3 of the field), intra-alveolar cell infiltrates (0:<5 intra-alveolar cells per
field; 1: 5 to 10 intra-alveolar cells per field; 2: 10 to 20 intra-alveolar cells per field; 3:>20
intra-alveolar cells per field) and alveolar hemorrhage (0: no hemorrhage; 1: at least 5 erythro-
cytes per alveolus in 1 to 5 alveoli; 2: at least 5 erythrocytes per alveolus in 5 to 10 alveoli; 3: at
least 5 erythrocytes per alveolus in>10 alveoli). Lung injury score was produced by the sum of
the three independent variables.
The average value of histological score determined for the small intestine and for the lungs
of each animal was pooled with those determined for the other animals of the same experimen-
tal group and the median value was determined. Quantitative analyses of the height of intesti-
nal villi (V) and depth of intestinal crypts (C) were performed using ImageJ software following
the method described by Pires et al. [28]. The mean villus height, crypt depth and villus/crypt
ratio were calculated for each animal and pooled with those determined for other animals of
the same experimental group.
2.12 Goblet cells analysis
Hematoxylin-eosin stained sections of intestinal tissues were stained for mucin-containing
Goblet cells and mucous production using periodic acid-Schiff (PAS). The number of Goblet
cells was counted in each section: the average number of Goblet cells per section was deter-
mined for each animal and then pooled with those determined for the other animals of the
same experimental group and the mean value was calculated.
2.13 Source of drugs and chemicals
Myeloperoxidase was purchased from Calbiochem (Darmstadt, Germany). Sodium dodecyl
sulphate and aprotinin were purchased from PanReac AppliChem ITW Reagents (Darmstadt,
Germany). KCl and acetic acid were purchased from Analar Normapur, VWR (Dublin, Ire-
land). All other chemicals of reagent grade were obtained from Sigma Aldrich (St. Louis, MO,
USA).
2.13 Statistical analysis
Data are expressed as means ± standard error (SE) unless otherwise specified. Comparison
among groups was made using two-way or one-way analysis of variance (ANOVA) followed
respectively by Bonferroni’s or Dunn’s post-test (P<0.05, P<0.01 and P<0.001 indicate
respectively statistically significant, highly significant and extremely significant differences).
All analyses were performed using Prism 5 program (GraphPad Soft-ware Inc., San Diego,
CA) on a Macintosh computer.
Intestinal ischemia/reperfusion injury and Bifidobacterium bifidum PRL2010
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3. Results
3.1 B. bifidumPRL2010 administration attenuates intestinal ischemia/
reperfusion (I/R) injury
In order to assess the activity of B. bifidum PRL2010 against intestinal I/R injury under in vivo
conditions, mice were pretreated with 109 CFU/day of B. bifidum PRL2010 for five consecutive
days before transient occlusion of SMA. Data were compared with sham operated (SO) mice
supplemented with B. bifidum PRL2010 following the same experimental procedures except
for SMA occlusion. Furthermore, two control groups were included [i.e., vehicle-treated I/R
and SO mice]. B. bifidum PRL2010 colonization was monitored by quantitative-real time PCR
on fecal samples collected at various time points during the experiment (S1 Fig).
Notably, we found that in vehicle-treated mice, ischemic injury of 45 min followed by 5 h
reperfusion significantly increased mortality (7 mice died out of 20 animals subjected to I/R)
and augmented intestinal MPO activity, considered as an index of neutrophil accumulation,
when compared with SO animals (P<0.001). Oral administration of B. bifidum PRL2010 did
not improve survival of mice (8 mice died out of 23 animals subjected to I/R) but decreased
neutrophil infiltration induced by I/R and slightly increased that triggered by simple intestinal
manipulation in SO group, when compared to the respective vehicle-treated animals (Fig 1A).
Furthermore, in lung tissues, MPO activity was significantly increased as a result of intestinal
I/R injury when compared to MPO values obtained for SO mice (P<0.001). Notably, B. bifi-
dum PRL2010 pre-treatment was shown to significantly decrease leukocyte recruitment in I/R
mice when compared to the corresponding control group (P<0.01) (Fig 1B).
Oxidative stress plays a key role in the pathogenesis of several clinical conditions, such as
neurological disorder, diabetes, aging, and lung disease and, in particular, gastrointestinal dis-
orders [29]. The transient occlusion of SMA augmented, although not significantly, intestinal
tissue malondialdehyde levels, index of lipid peroxidation, compared to those of SO mice.
Fig 1. Effects of B. bifidumPRL2010 on myeloperoxidase activity in I/R mice. MPO activity, index of neutrophil infiltration, assessed in intestinal (a) and lung (b)
tissue excised from SO (white columns) and I/R (black columns) mice orally administered with vehicle (Control), or supplemented with B. bifidum PRL2010 (n = 8–10
animals per group). Two-way ANOVA followed by Bonferroni’s post test: #P<0.05; ###P<0.001 vs. corresponding SO mice; P<0.01 vs. corresponding vehicle-treated
group.
https://doi.org/10.1371/journal.pone.0202670.g001
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Following B. bifidum PRL2010 treatment, comparable values of oxidative stress were observed
in SO and I/R mice (Fig 2A).
Moreover, a consistent increase in gut vascular permeability was detected after I/R injury in
the control group (P<0.01). Five-days administration of B. bifidum PRL2010 was ineffective in
counteracting the I/R-induced plasma extravasation (Fig 2B).
3.2 Pretreatment with B. bifidumPRL2010 prevents bacterial translocation
to distant organs
The loss of gut barrier function may cause bacterial translocation from the gut to peripheral
organs [3]. In this context, we investigated bacterial translocation in several tissues collected
from euthanized mice by means of qPCR. Interestingly, qPCR data highlighted that no bacteria
could be detected in a numbers of organs and tissues assayed (e.g. blood, liver, kidney and
spleen) excised from SO mice or in blood and spleen of I/R mice. Mesenteric I/R damage elic-
ited a massive increase of bacterial translocation to peripheral organs such as liver and kidneys.
However, oral administration of B. bifidum PRL2010 in I/R mice was shown to significantly
reduce the bacterial translocation levels in both organs (P<0.01 for kidneys and P<0.001 for
liver) (Fig 3).
3.3 Impact of B. bifidum PRL2010 on selected immune parameters
In order to explore the impact of B. bifidum PRL2010 on cytokines expression in organs such
as liver and kidneys, we evaluated the induction of genes encoding for IL-10, IL-12, IL-8 and
TNFalpha. In this context, we noticed different cytokine profile patterns between I/R mice
supplemented with B. bifidum PRL2010 and I/R mice supplemented with the vehicle. Notably,
tumor necrosis factor TNFalpha showed lower levels in liver and kidneys of mice subjected to
intestinal I/R supplemented with B. bifidum PRL2010 with respect to mice subjected to intesti-
nal I/R supplemented with vehicle. Furthermore, the supplementation of B. bifidum PRL2010
to I/R mice was shown to elicit a significant induction in kidneys of interleukin IL-12 and a
Fig 2. Effects of B. bifidumPRL2010 on oxidative stress and vascular permeability in I/R mice. MDA levels (a) and edema (b), expressed as wet-to-dry weight ratio,
in intestinal tissues excised from SO (white columns) and I/R (black columns) mice orally administered with vehicle (Control) or supplemented with B. bifidum
PRL2010 (n = 8–10 animals per group). Two-way ANOVA followed by Bonferroni’s post test: #P<0.05; ##P<0.01 vs. corresponding SO mice.
https://doi.org/10.1371/journal.pone.0202670.g002
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lower interleukin IL-10 response both in the liver and in kidneys compared to vehicle-treated
I/R mice (Fig 4).
The cytokine response of I/R mice treated with B. bifidum PRL2010 reinforced the notion
that B. bifidum PRL2010 strain influences host innate immunity, an observation consistent
with previous publications [14, 17].
3.4 B. bifidumPRL2010 and histology
Laparotomy and manipulation of the small intestine in SO mice produced a moderate expan-
sion of the sub-epithelial space with lifting of the epithelial layer both in vehicle- (Fig 5A) and
in B. bifidum PRL2010-treated (Fig 5B) mice. SMA occlusion for 45 minutes followed by 5h
reperfusion caused a massive injury of intestinal mucosa with denudation of villi, digestion
and disintegration of lamina propria, hemorrhage and ulceration, as shown by Fig 5C and by
semi-quantitative scoring of gut injury (Fig 6A). Pre-treatment with B. bifidum PRL2010 was
not effective in preserving mucosal integrity and in counteracting the remarkable I/R-induced
intestinal damage (Figs 5D and 6A). The morphometric analysis confirmed the broad destruc-
tion of mucosal architecture provoked by mesenteric I/R and the inefficacy of B. bifidum
PRL2010 in preventing it. Besides the difficulty in detecting villi to be measured after SMA
Fig 3. Effects of B. bifidumPRL2010 on bacterial translocation in I/R mice. qPCR analysis evaluated bacterial translocation in liver and kidneys samples excised from
SO (white columns) and I/R (black columns) mice orally administered with vehicle (Control) or supplemented with B. bifidum PRL2010 (n = 5 animals per group). Each
pillar represents the mean±SD of the log-transformed population size. Two-way ANOVA followed by Bonferroni’s post test: ##P<0.01, ###P<0.001 vs. corresponding SO
mice; P<0.01, P<0.001 vs. vehicle-treated I/R mice.
https://doi.org/10.1371/journal.pone.0202670.g003
Intestinal ischemia/reperfusion injury and Bifidobacterium bifidum PRL2010
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Fig 4. Effects of B. bifidumPRL2010 on the cytokine response in I/R mice. Panel a displays the relative transcription levels of IL-8, IL-10, IL-12 and TNFalpha in the
liver of I/R mice supplemented with vehicle (designated with red circles) or with B. bifidum PRL2010 (designated with black squares). Panel b shows the relative
transcription levels of the same cytokines in the kidneys of I/R mice supplemented with vehicle (red circles) or with B. bifidum PRL2010 (black squares). P<0.001 vs.
vehicle-treated I/R mice, Student’s t-test. The y-axis represents the normalized expression level (ΔCt) according to CFX96 Bio-Rad software.
https://doi.org/10.1371/journal.pone.0202670.g004
Intestinal ischemia/reperfusion injury and Bifidobacterium bifidum PRL2010
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occlusion, their height was markedly reduced compared with those in SO tissues (Fig 6B); sim-
ilarly, the values of villi/crypts (V/C) ratios were curtailed in I/R tissues with respect to SO
ones (Fig 6C). In both cases, the probiotic did not produce any significant improvement. As
regards the number of Goblet cells, visualized by PAS staining, no changes were produced by
supplementation with B. bifidum PRL2010 in SO mice; similarly, the dramatic reduction in
their number, mainly ensuing from the mucosal degeneration caused by intestinal hypoxia,
was only slightly attenuated by the short treatment with the probiotic (Fig 6D).
As regards lung histological injury, laparotomy and small intestine manipulation caused
only rare phenomena of septae congestion and very weak neutrophil infiltration, both in vehi-
cle- and in B. bifidum PRL2010-treated rats (Fig 7A, 7B and 7E). Mesenteric I/R produced
strong morphological changes in the lungs, inducing extensive congestion of septae, inter- and
Fig 5. Intestinal histology. Representative micrographs of hematoxylin-eosin and PAS stained sections of jejunal-ileal specimens harvested from SO animals treated
with vehicle (a) and B. bifidum PRL2010 (b) and from I/R mice pre-treated with vehicle (c) and B. bifidum PRL2010 (d) (scale bar: 100μm). Moderate expansion of
Gruenhagen’s spaces (indicated by arrows in a and b) was visible both in vehicle- and in probiotic-treated SO mice. Mesenteric I/R caused extensive denudation of villi
and, in some regions, digestion and disintegration of lamina propria (indicated by the arrow in c), with hemorrhages and ulceration; pre-treatment with B. bifidum
PRL2010 was not able to prevent the I/R-induced mucosal lesions (indicated by the arrow in d).
https://doi.org/10.1371/journal.pone.0202670.g005
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intra-alveolar infiltration of neutrophils and intra-alveolar hemorrhages (Fig 7C). Supplemen-
tation with B. bifidum PRL2010 attenuated lung injury: only moderate hyperemia of inter-alve-
olar capillaries and low-grade inter- and intra-alveolar infiltration of neutrophils and
erythrocytes could be detected in I/R lungs (Fig 7D and 7E).
Fig 6. Intestinal morphometry. Panel a represents histological damage scoring of intestinal sections (horizontal bar at the median value) according to Chiu’s score [26].
Height of villi (μm) (b), V/C ratio (c) and number of Goblet cells (d) in intestinal tissues excised from SO (white columns) and I/R (black columns) mice orally
administered with vehicle (Control) or supplemented with B. bifidum PRL2010 (n = 3–4 animals per group). Two-way ANOVA followed by Bonferroni’s post test:
##P<0.01 vs. corresponding SO mice.
https://doi.org/10.1371/journal.pone.0202670.g006
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4. Discussion
In the present study, the transient occlusion of SMA triggered an extensive intestinal mucosal
damage associated to an intense local and systemic inflammatory response: massive neutrophil
infiltration in the gut and lung districts, marked increase of gut and lung vascular permeability
and oxidative stress, remote bacterial translocation and TNFalpha and IL-10 up-regulation in
liver and kidneys occurred. In these experimental conditions, we observed that a five-days
treatment with B.bifidum PRL2010 was able to attenuate mesenteric I/R-induced changes: in
fact, pre-treatment with probiotic dampened neutrophil infiltration, especially at the pulmo-
nary level, moderately reduced oxidative stress and significantly decreased bacterial transloca-
tion and TNFalpha and IL-10 liver and kidneys transcription levels, while increasing those of
IL-12 in kidneys. These findings are in line with Wang research, that recently demonstrated
that 14 days oral pre-treatment with a pool of bifidobacteria was able to increase the expression
of tight junctions proteins and to reduce bacterial translocation from gut to distant organs
[30].
As concerns the evaluation of local inflammatory parameters, B. bifidum PRL2010 exerted a
slight beneficial effect on neutrophils infiltration and lipid peroxidation in the gut after I/R
injury, lowering MPO activity and driving MDA levels closer to the respective SO mice. B. bifi-
dum PRL2010 previously showed immunomodulatory properties stimulating the host immune
system during colonization and inducing different host genes expression. Among the main
targeted genes, some chemokines and HSP encoding genes resulted down regulated, while
defensin and tight junctions genes were up regulated [14, 17, 31]. On the basis of those immu-
nomodulatory properties, the slight increase of neutrophil recruitment and lipid peroxidation
observed in treated SO mice could be explained as a reinforcement of the innate system driven
by the B. bifidum PRL2010, which might contribute to mitigate the degree of inflammation
evoked by mesenteric I/R.
In our study, pre-treatment with B. bifidum PRL2010 did not affect intestinal plasma
extravasation and did not preserve mucosal integrity, possibly due to the extensive damage
triggered by hypoxia in our experimental model of mesenteric I/R. However, the remarkable
reduction in leukocytes recruitment and the preservation of alveolocapillary membranes in the
lungs, documented by biochemical and histological assays, along with the prevention of bacte-
rial translocation and decrease of TNFalpha transcription levels in kidneys and liver highlight
an undisputable protective action mediated by B. bifidum PRL2010. By now, it is well-known
that, following transient mesenteric hypoxia, the loss of mucosal barrier integrity and the ensu-
ing surge of luminal bacteria and toxins into the systemic circulation play a crucial role in the
systemic inflammatory response syndrome (SIRS) and multi-organ dysfunction syndrome
(MODS), primary causes of death after gut I/R [4]. Among different organs, lung is the most
frequently compromised after mesenteric I/R injury, and respiratory failure is the first symp-
tom of MODS. The favourable effects shown by B. bifidum PRL2010 in our experimental
model testify therefore its ability to dampen the inflammatory response, confining it to the gut,
and to prevent the involvement of distant organs in I/R-induced injuries.
The mechanism underlying this beneficial effect remains to be defined. Previous in vitro
investigations demonstrated the ability of B. bifidum PRL2010 to reinforce epithelial barrier
Fig 7. Lung histology. Representative hematoxylin-eosin stained sections of lung specimens harvested from SO animals treated with vehicle (a) and B. bifidum
PRL2010 (b) and from I/R mice pre-treated with vehicle (c) and B. bifidum PRL2010 (d) (scale bar: 100μm). The acute lung injury caused by mesenteric I/R
was characterized by diffuse congestion of septae, inter- and intra-alveolar cell infiltration and hemorrhage (c); pre-treatment with B. bifidum PRL2010
attenuated lung injury in all treated mice (d). Damage scoring of lung histological sections, according to Matute-Bello et al. [27], reported in panel e, shows the
ability of B. bifidum PRL2010 to alleviate the I/R-induced remote injury (e).
https://doi.org/10.1371/journal.pone.0202670.g007
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function through the stimulation of mucin secretion and by inhibiting the adhesion of patho-
genic bacteria such as E. coli and C. sakazakii [15] whose overgrowth has been reported to play
a key role in promoting bacterial translocation [32]. The reduced bacterial translocation as
well as the decreased TNFalpha levels in liver and kidneys of I/R mice supplemented with B.
bifidum PRL2010 compared to vehicle-treated I/R mice could likely result from the inhibition
of pathogen bacteria adhesion to intestinal epithelium. On the other hand, less probable
appears the change in the number of Goblet cells as potential protective factor put in place by
B. bifidum PRL2010.
Another important aspect worth of consideration is the ability of B. bifidum PRL2010 to
stimulate the transcription of IL-12 while decreasing that of IL-10 in kidneys: this effect,
already documented in the cecal mucosa of Balb/c mice [14], could be interpreted as a further
proof of the immunostimulatory properties of this strain of B. bifidum. Indeed, starting from
this evidence, we can speculate that, following colonization, B. bifidum PRL2010 promotes
innate immunity responses and the release of IL-12 by macrophages and dendritic cells, simul-
taneously dampening that of the immune-suppressive cytokine IL-10. The subsequent activa-
tion of adaptive Th1 cells would eventually contribute to prevent the dissemination of gut
bacteria to remote organs. Similarly, lactobacilli, such as Lactobacillus casei Shirota or Lactoba-
cillus reuteri ATCC 23272, proved to induce Th1 cells via the increased production of IL-12
generated by native immune cells [33].
In conclusion, our findings suggest that short-time treatment of mice, subjected to mesen-
teric I/R, with B. bifidum PRL2010 was significantly effective in reducing bacterial transloca-
tion and the subsequent systemic inflammatory response, despite its apparent lack of efficacy
in protecting the intestinal barrier integrity. The treatment with this single strain could be
therefore helpful to prevent distal organs impairment, an issue considered the primary cause
of death from intestinal I/R injury: it is expected that longer periods of treatment provide addi-
tional benefits, eventually increasing also the rate of survival.
Supporting information
S1 Fig. Panel a shows a schematic representation of the design of the murine trial. Panel b
displays population sizes of B. bifidum PRL2010 strain transiently present in the intestine of
Swiss mice (n = 14). Each point represents the average of the log-transformed population
size ± standard deviation. On x axis the time of feces collection is indicated with T0 = before B.
bifidum PRL2010 administration, T1 = 1 day, T2 = 4 days and T3 = 7 days after the beginning
of B. bifidum PRL2010 administration.
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